TELA Bio, Inc. (TELA)

↓ Download CSV

CIK 0001561921 · Nasdaq · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, TELA Bio, Inc. reported revenue of $80.28M, up 15.8% from the prior year. The company ran a net loss, with a net margin of -48.4% and a gross margin of 67.7%. It held $81.42M in total assets against $75.11M in total liabilities.

Key ratios (FY2025)

67.7%
Gross margin
-42.0%
Operating margin
-48.4%
Net margin
-615.1%
Return on equity
+15.8%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$80.28M$69.30M$58.45M$41.42M$29.46M$18.21M$15.45M$8.27M$4.25M
Gross Profit$54.34M$46.49M$40.11M$27.04M$18.81M$11.23M$9.27M$2.94M$2.53M
Operating Income-$33.76M-$34.12M-$44.08M-$39.01M-$29.45M-$25.27M-$19.16M-$17.78M-$16.92M
Net Income-$38.83M-$37.84M-$46.66M-$44.30M-$33.28M-$28.79M-$22.43M-$21.09M-$21.33M
EPS (Diluted)$-0.83$-1.33$-2.04$-2.72$-2.30$-2.23$-17.10
Total Assets$81.42M$86.57M$78.05M$67.86M$62.54M$86.46M$67.92M$27.23M
Total Liabilities$75.11M$58.11M$59.17M$53.55M$42.45M$37.43M$36.96M$40.94M
Shareholders' Equity$6.31M$28.46M$18.88M$14.30M$20.10M$49.03M$30.96M-$137.86M-$108.17M-$81.17M
Cash & Equivalents$50.84M$52.67M$46.73M$42.02M$43.93M$74.39M$45.30M$17.28M
Operating Cash Flow-$28.22M-$41.59M-$40.86M-$40.75M-$30.43M-$24.46M-$25.52M-$19.92M-$16.37M
Capital Expenditures$448.0K$989.0K$611.0K$872.0K$627.0K$167.0K$197.0K$62.0K$114.0K
Shares Outstanding44.54M39.40M24.49M19.17M14.53M14.44M11.41M295.7K